Gene therapy for atherosclerosis

International Journal of Clinical and Laboratory Research

Volumn 27, Issue 1, 1997, Pages 35-43

  Rader, D J ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Atherosclerosis; Gene therapy; Lipoproteins; Vectors

Indexed keywords

ANIMALIA;

EID: 0030850078     PISSN: 09405437     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02827240     Document Type: Article

References (85)

1. Manson JE, Tosterson H, Ridker PM, Satterfield S, Hebert P, O'Connor GT, Buring JE, Hennekens CH. The primary prevention of myocardial infarction. N Engl J Med 1992; 326:1406.
2. Smith J, Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ, Gotto AM, Gould KL, Greenland P, Grundy SM, Hill MN, Hlatky MA, Houston-Miller N, Krauss RM, LaRosa J, Ockene IS, Oparil S, Pearson TA, Rapaport E, Starke RD. Preventing heart attack and death in patients with coronary disease. Circulation 1995; 92:2.
3. Wilson JM. Animal models of human disease for gene therapy. J Clin Invest 1996, 97:1138.
4. Salmons B, Gunzberg WH. Targeting of retroviral vectors for gene therapy. Hum Gene Ther 1993; 4:129.
5. Rettinger S, Kennedy S, Wu X, Saylors R, Hafenrichter D, Flye W, Ponder KP. Liver-directed gene therapy: quantitative evaluation of promoter elements by using in vivo retroviral transduction. Proc Natl Acad Sci USA 1994; 91:1460.
6. Berkner K. Development of adenovirus vectors for the expression of heterologous genes. BioTechnology 1988; 6:616.
7. Kozarsky KF, Wilson JM. Gene therapy: adenovirus vectors. Curr Opin Genet Dev 1993; 3:499.
8. Wilson JM. Adenoviruses as gene-delivery vehicles. N Engl J Med 1996; 334:1185.
9. Willnow TE, Sheng Z, Ishibashi S, Herz J. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist. Science 1994; 264:1471.
10. Descamps V, Blumenfeld N, Villeval J-L, Vainchenker W, Perricaudet M, Beuzard Y. Erythropoietin gene transfer and expression in adult normal mice: use of an adenovirus vector. Hum Gene Ther 1994; 5:979.
11. Fang B, Eisensmith RC, Li XHC, Finegold MJ, Shedlovsky A, Dove W, Woo SLC. Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer. Gene Ther 1994; 1:247.
12. Herz J, Gerard RD. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. J Clin Invest 1993; 90:2812.
13. Spady KD, Cuthbert JA, Willard MN, Meidell RS. Adenovirus-mediated transfer of a gene encoding cholesterol 7α-hydroxylase into hamsters increases hepatic enzyme activity and reduces plasma total and low density lipoprotein cholesterol. J Clin Invest 1995; 96:700.
14. Tsukamoto K, Kowala M, Recce R, Rader DJ. Liver-directed gene transfer of apolipoprotein E by a second generation recombinant adenovirus decreases progression of atherosclerotic lesions in cholesterol-fed hamsters (abstract). Circulation 1995; 92:I-502.
15. Kozarsky KF, McKinley DR, Austin LL, Raper SE, Stratford-Perricaudet LD, Wilson JM In vivo correction of low density lipoprotein receptor deficiency in the watanabe heritable hyperlipidemic rabbit with recombinant adenovireses. J Biol Chem 1994; 269:13695.
16. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci 1994; USA 91:4407.
17. Yang Y, Ert HCJ, Wilson JM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994; 1:433.
18. Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves Iransgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994; 91:6196
19. Ye X, Robinson M, Batshaw M, Furth E, Smith I, Wilson JM. Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors. J Biol Chem 1996; 271:3639.
20. Tsukamoto K, Hiester K, Rader DJ. Prolonged expression of three apoE isoforms in apoE deficient mice using second generation adenoviruses and effect on lipoproteins (abstract). Circulation 1996; 94:I-591.
21. Kotin RM. Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum Gene Ther 1994; 5:793.
22. Ledley F. Nonviral gene therapy: the promise of genes as pharmaceutical products. Hum Gene Ther 1996; 6:1129.
23. Zhu N, Liggitt D, Debs R. Systemic gene expression after intravenous DNA delivery into adult mice. Science 1993; 261:209.
24. Kaneda Y, Iwai K, Uchida T. Increased expression of DNA co-introduced with nuclear protein in adult rat liver. Science 1989; 243:375.
25. Wu G, Wilson JM, Shalaby F, Grossman M, Shafritz D, Wu C. Receptor-mediated gene delivery in vivo. Partial correction of genetic analbuminemia in nagase rats. J Biol Chem 1991; 266: 14338.
26. Michael S, Curiel DT. Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway. Gene Ther 1994; 1:223.
27. Wagner E, Zatloukal K, Gotten M, Kirlappos H, Mechtler K, Curiel DT, Birnstiel ML. Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc Natl Acad Sci USA 1992; 89:6099.
28. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232:34.
29. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992; 1:445.
30. Gordon BR, Stein E, Jones P, Illingworth DR. Indications for low-density liproprotein apheresis. Am J Cardiol 1994; 74:1109.
31. Ishibashi S, Goldstein J, Brown M, Herz J, Burns D. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest 1994; 93:1885.
32. Chowdhury JR, Grossman M, Gupta S, Chowdhury NR, Baker J, Wilson JM. Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits. Science 1991; 254:1802.
33. Raper SE, Grossman M, Rader DJ, Thoene JG, Clark BJ III, Kolansky DM, Muller DWM, Wilson JM. Safety and feasibility of liver-directed ex vivo gene therapy for hypercholesterolemia. Ann Surg 1996; 223:116.
34. Grossman M, Rader DJ, Muller DWM, Kolansky DM, Kozarsky K, Clark BJ III, Stein EA, Lupien PJ, Brewer J, Raper SE, Wilson JM. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995; 1:1148.
35. Ishibashi S, Brown M, Goldstein J, Gerard R, Hammer R, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993; 92:883.
36. Beisiegel U. Receptors for triglyceride-rich lipoproteins and their role in lipoprotein metabolism (review). Curr Opin Lipidol 1995; 6:117.
37. Kozarsky K, Jooss K, Donahee M, Strauss JF, Wilson JM. Effective treatment of familial hypercholesterolemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nat Genet 1996; 13:54.
38. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989; 320:904.
39. Schaefer EJ, Gregg RE, Ghiselli G, Forte TM, Ordovas JM, Zech LA, Brewer HB Jr. Familial apolipoprotein E deficiency. J Clin Invest 1986; 78:1206.
40. Plump AS, Smith JD, Hayek T, Aalto-Setälä K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71:343.
41. Zhang S, Reddick R, Piedrahita J, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258:468.
42. Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science 1995; 267:1034.
43. Stevenson S, Marshall-Neff J, Teng B, Lee C, Roy S., McClelland A. Phenotypic correction of hypercholesterolemia in apoE-deficient mice by adenovirus-mediated in vivo gene transfer. Arterioscler Thromb Vasc Biol 1995; 15:479
44. Kashyap VS, Santamarina-Fojo S, Brown DR, Parrott CL, Applebaum-Bowden D, Meyn S, Talley G, Paigen B, Maeda N, Brewer HB Jr. Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors. J Clin Invest 1995; 96:1612.
45. Norum RA, Lakier JB, Goldstein S, Angel A, Goldberg RB, Block WD, Noffze DK, Dolphin PJ, Edelglass J, Bogorad DD, Alaupovic P. Familial deficiency of apolipoproteins A-I and C-III and precocious coronary-artery disease. N Engl J Med 1982; 306:1513.
46. Schaefer EJ, Heaton WH, Wetzel MG, Brewer HB Jr. Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease. Arteriosclerosis 1982; 2:16.
47. Ng D, Leiter L, Vezina C, Connelly P, Hegele R. Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia. J Clin Invest 1994; 93:223.
48. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the multiple risk factor intervention trial (MRFIT). JAMA 1986; 256:2823.
49. Li H, Reddick R, Maeda N. Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler Thromb 1993; 13:1814.
50. Fojo SS, Brewer HB Jr. The familial hyperchylomicronemia syndrome. JAMA 1991; 265:904.
51. Benlian P, DeGennes J, Foubert L, Zhang H, Gagne S, Hayden M. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med 1996; 335:848.
52. Hegele R, Little JA, Vezina C, Maguire G, Tu L, Wolever T, Jenkins D, Connelly P. Hepatic lipase deficiency: clinical, biochemical, and molecular genetic characteristics. Arterioscler Thromb 1993; 13:720.
53. Applebaum-Bowden D, Kobayashi J, Kashyap V, Brown D, Berard A, Meyn S, Parrott C, Maeda N, Shamburek R, Brewer HB, Santamarina-Fojo S. Hepatic lipase gene therapy in hepatic-lipase deficient mice. Adenovirus-mediated replacement of a lipolytic enzyme to the vascular endothelium. J Clin Invest 1996; 97:799.
54. Breslow JL. Mouse models of atherosclerosis. Science 1996; 272:685.
55. Yamada N, Shimano H, Mokuno H, Ishibasi S, Gotohda T, Kawakami M, Watanabe Y, Akanuma Y, Murase T, Takaku F. Increased clearance of plasma cholesterol after injection of apolipoprotein E into Watanabe heritable hyperlipidemic rabbits. Proc Natl Acad Sci USA 1989; 86:665.
56. Shimano H, Yamada N, Katsuki M, Shimada M, Gotoda T, Harada K, Murase T, Fukazawa C, Takaku F, Yazaki Y. Overexpression of apolipoprotein E in transgenic mice: marked reduction in plasma lipoproteins except high density lipoprotein and resistance against diet-induced hypercholesterolemia. Proc Natl Acad Sci USA 1992; 89:1750.
57. Shimano H, Yamada N, Katsuki M, Yamamoto K, Gotoda T, Harada K, Shimada M, Yazaki Y. Plasma lipoprotein metabolism in transgenic mice overexpressing apolipoprotein E. Accelerated clearance of lipoproteins containing apolipoprotein B. J Clin Invest 1992; 90:2084.
58. Yamamoto K, Shimano H, Shimada M, Kawamura M, Gotoda T, Harada K, Ohsuga J, Yazaki Y, Yamada N. Overexpression of apolipoprotein E prevents development of diabetic hyperlipidemia in transgenic mice. Diabetes 1995; 44:580.
59. De Silva H, Lauer S, Wang J, Simonet S, Weisgraber K, Mahley R, Taylor J. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem 1994; 269:2324.
60. Woollen LA, Osono Y, Herz J, Dietschy JM. Apolipoprotein E competitively inhibits receptor-dependent low density lipoprotein uptake by the liver but has no effect on cholesterol absorption or synthesis in the mouse. Proc Natl Acad Sci USA 1995; 92:12500.
61. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988; 8:1.
62. Brewer HB Jr, Zech LA, Gregg RE, Schwanz D, Schaefer EJ. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment. Ann Intern Med 1983; 98: 623.
63. Kwiterovich PO Jr. Genetics and molecular biology of fa-milial combined hyperlipidemia. Curr Opin Lipidol 1993; 4:133.
64. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973; 52:1544.
65. Yamada N, Inoue I, Kawamura M, Harada K, Watanabe Y, Shimano H, Gotoda T, Shimada M, Kohzaki K, Tsukada T, Shiomi M, Yazaki Y. Apolipoprotein E prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. J Clin Invest 1992; 89:706.
66. Shimano H, Ohsuga J, Shimada M, Namba Y, Gotoda T, Harada K, Katsuki M, Yazaki Y, Yamada N. Inhibition of diet-induced atheroma formation in transgenic mice expressing apolipoprotein E in the arterial wall. J Clin Invest 1995; 95:469.
67. Bellosta S, Mahley RW, Sanan DA, Murata J, Newland DL, Taylor JM, Pitas RE. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest 1995; 96:2170.
68. Tall AR. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest 1990; 86:379.
69. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 1990; 85:1234.
70. Miyazaki A, Sakuma S, Morikawa W, Takiue T, Miake F, Terano T, Sakai M, Hakamata H, Sakamoto Y, Naito M, Ruan Y, Takahashi K, Ohta T, Horiuchi S. Intravenous injection of rabbot apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 1995; 15:1882.
71. Emmanuel F, Caillaud JM, Hennuyer N, Fievet C, Viry I, Houdebin LM, Fruchart JC, Denefle P, Duverger N. Overexpression of human apolipoprotein A-I inhibits atherosclerosis development in Watanabe rabbits (abstract). Circulation 1996; 94: I-632.
72. Rubin E, Krauss R, Spangler E, Verstuyft J, Clift S. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991; 353:265.
73. Plump A, Scott C, Breslow J. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 1994; 91.9607
74. Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994; 94:899.
75. Kopfler WP, Willard M, Betz T, Willard JE, Gerard RD, Meidell RS. Adenovirus-mediated transfer of a gene encoding human apolipoprotein A-I into normal mice increases circulating high-density Hpoprotein cholesterol. Circulation 1994; 90:1319.
76. Duverger N, Ghalim N, Ailhaud G, Steinmetz A, Fruchart JC, Castro G. Characterization of apolipoprotein A-IV-containing Hpoprotein particles isolated from human plasma and interstitial fluid. Arterioscler Thromb 1993; 13:126.
77. Duverger N, Tremp G, Caillaud J, Emmanuel F, Castro G, Fruchart JC, Steinmetz A, Denefle P. Protection against atherosclerosis in mice mediated by human apolipoprotein A-IV. Science 1996; 273:966
78. Rader DJ, Ikewaki K. Unravelling high density lipoprotein-apolipoprotein metabolism in human mutants and animal models. Curr Opin Lipidol 1996; 7:117.
79. Mehlum A, Staels B, Duverger N, Tailleux A, Castro G, Fievet C, Luc G, Fruchart JC, Olivecrona G, Skretting G. Tissue-specific expression of the human gene for lecithin:cholesterol acyltransferase in transgenic mice alters blood lipids, lipoproteins and lipases towards a less atherogenic profile. Eur J Biochem 1995; 230:567.
80. Hoeg J, Vaisman B, Demosky S, Meyn S, Talley G, Hoyt R, Feldman S, Berard A, Sakai N, Wood D, Brousseau M, Marcovina S, Brewer HB, Santamarina-Fojo S. Lecithin:cholesterol acyltransferase overexpression generates hyperalphalipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits. J Biol Chem 1996; 271:4396.
81. Hoeg JM, Santamarina-Fojo S, Berard A, Cornhill JF, Herderick E, Feldman S, Haudenschild C, Vaisman B, Hoyt RF Jr, Demosky S, Kauffman R, Hazel C, Marcovina S, Brewer HB Jr. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci USA 1996; 93:11448.
82. Vaisman B, Berard A, Paigen B, Marcovina S, Eckhaus M, Maeda N, Brewer HB Jr, Santamarina-Fojo S. Overexpression of human lecithin cholesterol acyltransferase (LCAT) in LCAT transgenic and apoE deficient mice leads to enhanced atherosclerosis (abstract). Circulation 1996; 94.I-633.
83. Seguret-Mace S, Latta-Mahieu M, Castro G, Luc G, Fruchart JC, Rubin E, Denefle P, Duverger N. Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene. Circulation 1996; 94:2177.
84. Shimada M, Shimano H, Gotoda T, Yamamoto K, Kawamura M, Inaba T, Yazaki Y, Yamada N. Overexpression of human lipoprotein lipase in transgenic mice: resistance to diet-induced hypertriglyceridemia and hypercholesterolemia. J Biol Chem 1993; 268:17924.
85. Shimada M, Ishibashi S, Gotoda T, Kawamura M, Yamamoto K, Inaba T, Harada K, Ohsuga J, Perrey S, Yazaki Y. Overexpression of human lipoprotein lipase protects diabetic transgenic mice from diabetic hypertriglyceridemia and hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995; 15:1688.